Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Last updated: March 20, 2025
Sponsor: Handok Inc.
Overall Status: Active - Recruiting

Phase

1

Condition

Healthy Volunteers

Treatment

HD-P023

Empagliflozin High

Teneligliptin

Clinical Study ID

NCT06889350
HD-MP-108
  • Ages > 19
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this study is to compare the pharmacokinetics and safety of HD-P023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients who are 19 years or older on screening

  • Signed informed consent

  • Healthy Volunteer

  • Other inclusion applies

Exclusion

Exclusion Criteria:

  • Clinically relevant/significant findings as evaluated by the investigator

  • Other exclusion applied

Study Design

Total Participants: 40
Treatment Group(s): 3
Primary Treatment: HD-P023
Phase: 1
Study Start date:
March 01, 2025
Estimated Completion Date:
April 30, 2025

Connect with a study center

  • H Plus Yangji Hospital

    Seoul, 08779
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.